- Joining a number of other drugmakers this month, Johnson & Johnson (NYSE:JNJ) raised prices on about two dozen prescription drugs today, including top sellers Stelara (for psoriasis), Zytiga (for prostate cancer) and blood thinner Xarelto.
-
Most increases were in the 6-7% range, Reuters notes.
-
The company says average list price increase on its drugs will be 4.2% this year, but it expects net price it receives to drop after rebates and discounts. It says it doesn’t plan to raise prices on any more drugs this year.
-
Shares are down 0.4% after hours.
Source: Seeking Alpha
Leave a Reply